Active Stocks
Thu Oct 17 2024 15:58:31
  1. Tata Steel share price
  2. 152.35 -1.87%
  1. State Bank Of India share price
  2. 810.90 0.63%
  1. Reliance Industries share price
  2. 2,713.45 0.20%
  1. Wipro share price
  2. 528.80 -0.65%
  1. Tata Motors share price
  2. 891.70 -1.70%
Business News/Market/Market Stats/    Aurobindo Pharma

AUROBINDO PHARMA SUMMARY

Aurobindo Pharma is trading 1.13% lower at Rs 1466.00 as compared to its last closing price. Aurobindo Pharma has been trading in the price range of 1486.55 & 1464.3. Aurobindo Pharma has given 36.72% in this year & -1.81% in the last 5 days.

 

Aurobindo Pharma has TTM P/E ratio 20.09 as compared to the sector P/E of 32.9. There are 26 analysts who have initiated coverage on Aurobindo Pharma. There are 4 analysts who have given it a strong buy rating & 13 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.

 

The company posted a net profit of 919.22 Crores in its last quarter.

 

Listed peers of Aurobindo Pharma include Aurobindo Pharma (-1.13%), Pfizer (1.63%), Neuland Laboratories (-5.86%) etc.

 

Aurobindo Pharma has a 51.82% promoter holding & 48.18% public holding.

FAQs about Aurobindo Pharma

Aurobindo Pharma is trading at 1466.00 as on 17 Oct, 2024 3:29:36 PM. This is -1.13% lower as compared to its previous closing price of 1482.7
The market capitalization of Aurobindo Pharma is 86077.71 Cr as on 17 Oct, 2024 3:29:36 PM.
The average broker rating on Aurobindo Pharma is Buy. The breakup of analyst rating is given below -
  • 2 analysts have given a strong sell rating
  • 2 analysts have given a sell rating
  • 5 analysts have given a hold rating
  • 13 analysts have given a buy rating
  • 4 analysts have given a strong buy rating
The 52 wk high for Aurobindo Pharma is 1592.55 whereas the 52 wk low is 834.9
Aurobindo Pharma can be analyzed on the following key metrics -
  • TTM P/E: 20.09
  • Sector P/E: 32.9
  • Dividend Yield: 0.3%
  • D/E ratio: -
Aurobindo Pharma reported a net profit of 3172.97 Cr in 2024.
Recommended For You